Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15%…
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
After nearly seven years as a member of the Executive Committee of…
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class…
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12%…
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded…